Cargando…
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
BACKGROUND: Chemotherapy-induced peripheral neuropathy is commonly observed in patients treated with nanoparticle albumin–bound paclitaxel (nab-PTX). We conducted a multicenter randomized controlled study to evaluate the optimal dose of nab-PTX. METHODS: We compared three different doses of q3w nab-...
Autores principales: | Tsurutani, Junji, Hara, Fumikata, Kitada, Masahiro, Takahashi, Masato, Kikawa, Yuichiro, Kato, Hiroaki, Sakata, Eiko, Naito, Yoichi, Hasegawa, Yoshie, Saito, Tsuyoshi, Iwasa, Tsutomu, Taira, Naruto, Takashima, Tsutomu, Kashiwabara, Kosuke, Aihara, Tomohiko, Mukai, Hirofumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753189/ https://www.ncbi.nlm.nih.gov/pubmed/33341707 http://dx.doi.org/10.1016/j.breast.2020.12.002 |
Ejemplares similares
-
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
por: Taira, Naruto, et al.
Publicado: (2021) -
Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
por: Taira, Naruto, et al.
Publicado: (2021) -
Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: Miyahara, Kana, et al.
Publicado: (2022) -
Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer
por: Tsurutani, Junji, et al.
Publicado: (2015) -
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials
por: Kawahara, Takuya, et al.
Publicado: (2022)